{"id":4007,"date":"2013-07-08T00:00:00","date_gmt":"2013-07-08T04:00:00","guid":{"rendered":"https:\/\/icesontario.wpengine.com\/journal-articles\/cardiovascular-safety-of-inhaled-long-acting-bronchodilators-in-individuals-with-chronic-obstructive-pulmonary-disease\/"},"modified":"2023-06-14T19:26:45","modified_gmt":"2023-06-14T23:26:45","slug":"cardiovascular-safety-of-inhaled-long-acting-bronchodilators-in-individuals-with-chronic-obstructive-pulmonary-disease","status":"publish","type":"journal_article","link":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/cardiovascular-safety-of-inhaled-long-acting-bronchodilators-in-individuals-with-chronic-obstructive-pulmonary-disease\/","title":{"rendered":"Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease"},"content":{"rendered":"

Importance<\/strong> — Chronic obstructive pulmonary disease (COPD) is a common and deadly disease. Long-acting inhaled β-agonists and anticholinergics, first-line medications for COPD, have been associated with increased risk of cardiovascular outcomes. When choosing between the medications, patients and physicians would benefit from knowing which has the least risk.<\/p>\n

Objective<\/strong> — To assess the association of these classes of medications with the risk of hospitalizations and emergency department visits for cardiovascular events.<\/p>\n

Design<\/strong> — The researchers conducted a nested case-control analysis of a retrospective cohort study. The researchers compared the risk of events between patients newly prescribed inhaled long-acting β-agonists and anticholinergics, after matching and adjusting for prognostic factors.<\/p>\n

Setting <\/strong> — Healthcare databases from Ontario, the largest province of Canada, with a multicultural population of approximately 13 million.<\/p>\n

Participants<\/strong> — All individuals 66 years or older meeting a validated case definition of COPD, based on health administrative data, and treated for COPD from September 1, 2003, through March 31, 2009.<\/p>\n

Exposure<\/strong> — New use of an inhaled long-acting β-agonist or long-acting anticholinergic.<\/p>\n

Main Outcome and Measures<\/span> — An emergency department visit or a hospitalization for a cardiovascular event.<\/p>\n

Results<\/strong> — Of 191 005 eligible patients, 53 532 (28.0%) had a hospitalization or an emergency department visit for a cardiovascular event. Newly prescribed long-acting inhaled β-agonists and anticholinergics were associated with a higher risk of an event compared with nonuse of those medications (respective adjusted odds ratios, 1.31 [95% CI, 1.12-1.52; P < .001] and 1.14 [1.01-1.28; P = .03]). We found no significant difference in events between the 2 medications (adjusted odds ratio of long-acting inhaled β-agonists compared with anticholinergics, 1.15 [95% CI, 0.95-1.38; P = .16]). <\/p>\n

Conclusions and Relevance<\/span> — Among older individuals with COPD, new use of long-acting β-agonists and anticholinergics is associated with similar increased risks of cardiovascular events. Close monitoring of COPD patients requiring long-acting bronchodilators is needed regardless of drug class. <\/p>\n","protected":false},"excerpt":{"rendered":"

Importance — Chronic obstructive pulmonary disease (COPD) is a common and deadly disease. Long-acting inhaled β-agonists and anticholinergics, first-line medications for COPD, have been associated with increased risk of cardiovascular outcomes. When choosing between the medications, patients and physicians would benefit from knowing which has the least risk. Objective — To assess the association of […]<\/p>\n","protected":false},"template":"","migration-helper-automated":[],"migration-manual":[],"topic":[24,52],"migration-helper-qa-sample-set":[],"class_list":["post-4007","journal_article","type-journal_article","status-publish","hentry","topic-acute-and-emergency-services","topic-lung-health"],"acf":{"citation":"Gershon A, Croxford R, Calzavara A, To T, Stanbrook MB, Upshur R, Stukel TA. JAMA Intern Med<\/em>. 2013; 173(13):1175-85.","source_url":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/1710084","ices_scientist":[1244,1372,1349],"site":[6733],"research_program":[6746,6740],"news_release":[7443],"journal_article":[],"atlas":[],"research_report":[],"infographic":[],"video":[],"downloads":null,"links":null,"sitecore_item_id":"24B20E59-ECE2-4B31-A082-27DB26D60F6E","sitecore_item_name":"Cardiovascular-safety-of-inhaled-long-acting-bronchodilators-in-individuals-with-chronic","sitecore_field_values":"{\n \"Title\": \"Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease\",\n \"Short title\": \"Cardiovascular safety of inhaled\",\n \"Citation\": \"

Gershon A, Croxford R, Calzavara A, To T, Stanbrook MB, Upshur R, Stukel TA. JAMA Intern Med<\/em>. 2013; 173(13):1175-85.<\/p>\",\n \"Abstract\": \"

Importance<\/strong> — Chronic obstructive pulmonary disease (COPD) is a common and deadly disease. Long-acting inhaled β-agonists and anticholinergics, first-line medications for COPD, have been associated with increased risk of cardiovascular outcomes. When choosing between the medications, patients and physicians would benefit from knowing which has the least risk.<\/p>n

Objective<\/strong> — To assess the association of these classes of medications with the risk of hospitalizations and emergency department visits for cardiovascular events.<\/p>n

Design<\/strong> — The researchers conducted a nested case-control analysis of a retrospective cohort study. The researchers compared the risk of events between patients newly prescribed inhaled long-acting β-agonists and anticholinergics, after matching and adjusting for prognostic factors.<\/p>n

Setting <\/strong> — Healthcare databases from Ontario, the largest province of Canada, with a multicultural population of approximately 13 million.<\/p>n

Participants<\/strong> — All individuals 66 years or older meeting a validated case definition of COPD, based on health administrative data, and treated for COPD from September 1, 2003, through March 31, 2009.<\/p>n

Exposure<\/strong> — New use of an inhaled long-acting β-agonist or long-acting anticholinergic.<\/p>n

Main Outcome and Measures<\/span> — An emergency department visit or a hospitalization for a cardiovascular event.<\/p>n

Results<\/strong> — Of 191 005 eligible patients, 53 532 (28.0%) had a hospitalization or an emergency department visit for a cardiovascular event. Newly prescribed long-acting inhaled β-agonists and anticholinergics were associated with a higher risk of an event compared with nonuse of those medications (respective adjusted odds ratios, 1.31 [95% CI, 1.12-1.52; P < .001] and 1.14 [1.01-1.28; P = .03]). We found no significant difference in events between the 2 medications (adjusted odds ratio of long-acting inhaled β-agonists compared with anticholinergics, 1.15 [95% CI, 0.95-1.38; P = .16]). <\/p>n

Conclusions and Relevance<\/span> — Among older individuals with COPD, new use of long-acting β-agonists and anticholinergics is associated with similar increased risks of cardiovascular events. Close monitoring of COPD patients requiring long-acting bronchodilators is needed regardless of drug class. <\/p>n

View full text<\/a><\/p>\",\n \"Keywords\": \"{6CF3F7C3-716A-435F-BFC9-A17A5FE763F9}|{EDACCF0C-A0D0-4496-9216-D3055A23BC38}|{636318BA-F652-4567-A4B3-0E00CEAE81E1}\",\n \"Related Products\": \"

News Release<\/h2>rn

Two common COPD drugs have similar increased risk of cardiovascular events<\/a><\/h3>\",\n \"Research Programs\": \"{CFE36C89-C969-4C23-B5E4-1BA9E5BDC273}|{46DF28D2-EDE8-4DF2-8CC0-87CEF464E435}|{5B1AF319-EC9B-4BF0-A9CD-D066ABE49D71}\",\n \"ICES Locations\": \"{4FCAABBA-14A5-42E6-8F33-BC6C2F1D9908}\",\n \"ICES Scientists\": \"{BC74234B-58F2-4366-95D9-235FF40A7AE3}|{7D75B0F9-45DF-42C8-9A99-B6B509E8223E}|{A0978F87-1C10-4E62-A833-89616146CA59}|{73142C55-DCAD-42CC-92F6-A9E364B0EF62}\",\n \"Posted Date\": \"20130708T000000\"\n}","previous_url":"https:\/\/www.ices.on.ca\/Publications\/Journal-Articles\/2013\/January\/Cardiovascular-safety-of-inhaled-long-acting-bronchodilators-in-individuals-with-chronic"},"yoast_head":"\nICES | Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease<\/title>\n<meta name=\"description\" content=\"Importance — Chronic obstructive pulmonary disease (COPD) is a common and deadly disease. Long-acting inhaled β-agonists and\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/cardiovascular-safety-of-inhaled-long-acting-bronchodilators-in-individuals-with-chronic-obstructive-pulmonary-disease\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ICES | Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease\" \/>\n<meta property=\"og:description\" content=\"Importance — Chronic obstructive pulmonary disease (COPD) is a common and deadly disease. Long-acting inhaled β-agonists and\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/cardiovascular-safety-of-inhaled-long-acting-bronchodilators-in-individuals-with-chronic-obstructive-pulmonary-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"ICES\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ICESOntario\/\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-14T23:26:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/cardiovascular-safety-of-inhaled-long-acting-bronchodilators-in-individuals-with-chronic-obstructive-pulmonary-disease\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/cardiovascular-safety-of-inhaled-long-acting-bronchodilators-in-individuals-with-chronic-obstructive-pulmonary-disease\\\/\",\"name\":\"ICES | Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\"},\"datePublished\":\"2013-07-08T04:00:00+00:00\",\"dateModified\":\"2023-06-14T23:26:45+00:00\",\"description\":\"Importance — Chronic obstructive pulmonary disease (COPD) is a common and deadly disease. Long-acting inhaled β-agonists and\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/cardiovascular-safety-of-inhaled-long-acting-bronchodilators-in-individuals-with-chronic-obstructive-pulmonary-disease\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/cardiovascular-safety-of-inhaled-long-acting-bronchodilators-in-individuals-with-chronic-obstructive-pulmonary-disease\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/cardiovascular-safety-of-inhaled-long-acting-bronchodilators-in-individuals-with-chronic-obstructive-pulmonary-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Journal Articles\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"name\":\"ICES\",\"description\":\"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\"},\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\",\"name\":\"ICES\",\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"contentUrl\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"width\":\"676\",\"height\":\"618\",\"caption\":\"ICES\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ICESOntario\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ices-research-institute\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ICES | Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease","description":"Importance — Chronic obstructive pulmonary disease (COPD) is a common and deadly disease. Long-acting inhaled β-agonists and","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/cardiovascular-safety-of-inhaled-long-acting-bronchodilators-in-individuals-with-chronic-obstructive-pulmonary-disease\/","og_locale":"fr_FR","og_type":"article","og_title":"ICES | Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease","og_description":"Importance — Chronic obstructive pulmonary disease (COPD) is a common and deadly disease. Long-acting inhaled β-agonists and","og_url":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/cardiovascular-safety-of-inhaled-long-acting-bronchodilators-in-individuals-with-chronic-obstructive-pulmonary-disease\/","og_site_name":"ICES","article_publisher":"https:\/\/www.facebook.com\/ICESOntario\/","article_modified_time":"2023-06-14T23:26:45+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/cardiovascular-safety-of-inhaled-long-acting-bronchodilators-in-individuals-with-chronic-obstructive-pulmonary-disease\/","url":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/cardiovascular-safety-of-inhaled-long-acting-bronchodilators-in-individuals-with-chronic-obstructive-pulmonary-disease\/","name":"ICES | Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease","isPartOf":{"@id":"https:\/\/www.ices.on.ca\/fr\/#website"},"datePublished":"2013-07-08T04:00:00+00:00","dateModified":"2023-06-14T23:26:45+00:00","description":"Importance — Chronic obstructive pulmonary disease (COPD) is a common and deadly disease. Long-acting inhaled β-agonists and","breadcrumb":{"@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/cardiovascular-safety-of-inhaled-long-acting-bronchodilators-in-individuals-with-chronic-obstructive-pulmonary-disease\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/cardiovascular-safety-of-inhaled-long-acting-bronchodilators-in-individuals-with-chronic-obstructive-pulmonary-disease\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/cardiovascular-safety-of-inhaled-long-acting-bronchodilators-in-individuals-with-chronic-obstructive-pulmonary-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ices.on.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Journal Articles","item":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/"},{"@type":"ListItem","position":3,"name":"Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease"}]},{"@type":"WebSite","@id":"https:\/\/www.ices.on.ca\/fr\/#website","url":"https:\/\/www.ices.on.ca\/fr\/","name":"ICES","description":"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE","publisher":{"@id":"https:\/\/www.ices.on.ca\/fr\/#organization"},"alternateName":"Institute for Clinical Evaluative Sciences","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ices.on.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ices.on.ca\/fr\/#organization","name":"ICES","alternateName":"Institute for Clinical Evaluative Sciences","url":"https:\/\/www.ices.on.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","contentUrl":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","width":"676","height":"618","caption":"ICES"},"image":{"@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ICESOntario\/","https:\/\/www.linkedin.com\/company\/ices-research-institute\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/journal_article\/4007","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/journal_article"}],"about":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/types\/journal_article"}],"acf:post":[{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/news_release\/7443"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/research_program\/6740"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/research_program\/6746"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/site\/6733"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1349"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1372"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1244"}],"wp:attachment":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/media?parent=4007"}],"wp:term":[{"taxonomy":"migration-helper-automated","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-helper-automated?post=4007"},{"taxonomy":"migration-manual","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-manual?post=4007"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/topic?post=4007"},{"taxonomy":"migration-helper-qa-sample-set","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-helper-qa-sample-set?post=4007"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}